Parkinsn's Email List Message
Posting to the Parkinsn List is a benefit of Subscription
New-New COMT study
In vivo effects of new inhibitors of catechol-O-methyl transferase
E Rivas, ML de Ceballos, O Nieto, JA Fontenla
British J Pharmacol 1999;126:1667-1673
A new nitrocatechol compound, QO IIR, is an effective, peripherally
acting, reversible inhibitor of COMT, according to this study.
Rats treated with reserpine to induce akinesia were given
intraperitoneal injections of either QO IIR, another new compound QO
IIA, or one of two known COMT inhibitors, nitecapone or R0-41-0960.
Levodopa/carbidopa was administered one hour later, and locomotor
activity was assessed one hour after that, recorded as total movement
counts per hour.
QO IIR, but not QO IIA, improved locomotor activity to a degree similar
to the two known COMT inhibitors. QO IIR was effective at doses ranging
from 11.25-30 mg/kg, with a drop off in effectiveness at higher doses.
--
Judith Richards, London, Ontario, Canada
<judithr@xxxxxxxx>
^^^
\ /
\ | / Today?s Research
\\ | // ...Tomorrow?s Cure
\ | /
\|/
```````
Parkinsn's Archive Treasures Doctors, students, patients and caregivers find current Parkinson's information such as the Algorithm, Caregivers Handbook, and talks by respected Movement Disorder Specialists.
Mail converted by MHonArc
2.6.10
Site Hosting donated by He.net
&
Grant from The Parkinson Alliance
